A USA-licensed physician

I am:

Before a Request is Made

Before deciding whether this drug might be appropriate for your patient, please read our Investigator’s Brochure and Scientific Overview which detail RLF-100’s mechanism of action, indications, dosing and administration, and known adverse events.

Request Expanded Access for your Patients

When you have finished reading the Investigator Brochure, if you would like to proceed with being registered and approved for the RLF100 Expanded Access Program, under which aviptadil may be made available for your patients, please begin by filling out the form below.

Please note that we are receiving a very high volume of requests
and we are working expeditiously to address these.

Name *

First

Last

Email *

Cell Phone *

Eligibility criteria #1 *

I am a US-licensed physician

Eligibility criteria #2 *

I am subspecialty-boarded and practice critical care medicine in the ICU setting.

Eligibility criteria #3 *

I am treating various patients who have Respiratory Failure caused by COVID-19 and my intensive care unit has treated more than 30 Critical COVID-19 patients since March 2020.

(Respiratory Failure is defined by the FDA as the requirement for mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen in excess of 20L/hr in order to maintain blood oxygen saturation.)

Eligibility criteria #4 *

I have exhausted all currently-approved therapeutic options that might reasonably help various of our patients (more than 1).

At this time, we are focused on institutions that expect to treat numerous patients under an Expanded Access Program.

Eligibility criteria #5 *

I understand that RLF-100 is an investigational drug for which no determination of safety or efficacy has been made by the US Food and Drug Administration.

Eligibility criteria #6 *

My hospital is prepared to accept the IRB oversight of the Advarra central IRB (www.advarra.com) and I recognize that neither the protocol nor the consent can be altered by my local IRB.

Eligibility criteria #7 *

My hospital has an investigational pharmacy – that is well prepared to receive, cold-chain (2-8º degrees Celsius) investigational products – such as Aviptadil, and preparing and dispensing a 12hr-18hr infusion with a very low infusion volume through a standard infusion pump

Eligibility criteria #8 *

My hospital has nursing staff that is skilled in administering investigational products, and closely monitoring patients accordingly, I or appropriately qualified physicians will be supervising this staff during administration.

Eligibility criteria #9

In addition to participating in the Expanded Access program, I would like to be considered as an investigator for your phase 3 clinical trials. My hospital has a research pharmacy and a clinical trials infrastructure

Message

Get information about the COVID-19 Expanded Access program

Learn more